Breast Cancer: Hr+/Her2-: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797445
  • Drug Pipelines
  • 273 pages
  • Datamonitor Healthcare
1 of 3
Ibrance’s continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market.

This report addresses the following questions:

- Which branded therapies will have the largest impact on the HR+/HER2- breast cancer market?
- What is the overall market potential for first-in-class product Ibrance?
- How will competing CDK4/6 inhibitors ribociclib and abemaciclib fare following the earlier launch of Ibrance?
- How will PI3K inhibitors alpelisib, buparlisib, and taselisib be positioned in the market?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: HR+/HER2 BREAST CANCER

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Abemaciclib
- Afinitor (everolimus)
- Alpelisib
- Avastin (bevacizumab)
- Buparlisib
- Entinostat
- Faslodex (fulvestrant)
- Halaven (eribulin mesylate)
- Ibrance (palbociclib)
- Ixempra (ixabepilone)
- Lynparza (olaparib)
- Niraparib
- Ribociclib
- Talazoparib
- Taselisib
- Veliparib
- Primary Research Methodology

TREATMENT: HR+/HER2 BREAST CANCER

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in HR+/HER
- Breast Cancer

EPIDEMIOLOGY: HER+/HER2 BREAST CANCER

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: HR+/HER2 BREAST CANCER

- Executive Summary
- Product Overview ,
- Product profile: Afinitor
- Product profile: Avastin
- Product profile: Faslodex
- Product profile: Halaven
- Product profile: Ibrance
- Product profile: Ixempra

PIPELINE: HR+/HER2 BREAST CANCER

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Product profile (late stage): Lynparza
- Product profile (late stage): abemaciclib
- Product profile (late stage): alpelisib
- Product profile (late stage): buparlisib
- Product profile (late stage): entinostat
- Product profile (late stage): niraparib
- Product profile (late stage): ribociclib
- Product profile (late stage): talazoparib
- Product profile (late stage): taselisib
- Product profile (late stage): veliparib
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll